NASDAQ$LIVN
LivaNova PLC · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported a decrease in worldwide sales due to COVID-19 impact, but implemented actions to reduce expenses and improve liquidity.
LivaNova reported a significant decrease in sales for Q2 2020 due to the impact of COVID-19 on procedure volumes and capital equipment purchases. The company responded by reducing expenses and improving liquidity. While COVID-19 continues to impact the business, there are encouraging signs of gradual improvement in procedure volumes and new product releases.
- Worldwide sales decreased by 34.3% on a reported basis and 33.1% on a constant-currency basis compared to Q2 2019.
- GAAP diluted loss per share from continuing operations was $1.81, while adjusted diluted loss per share was $0.15.
- Implemented actions to reduce expenses, improve liquidity, and increase financial flexibility in response to current conditions.
- Encouraged by gradual improvement in procedure volumes, full commercial release of LifeSPARC in the U.S., and launch of Perceval® Plus in Europe.
Headline financials
Revenue & EPS history
LivaNova · Revenue · Quarterly
$182M
Revenue by segment
LivaNova · $159M total across 3 segments · Q2 2020
- Cardiopulmonary$101M-22.6%63.7%
- Neuromodulation$57.2M-45.2%36.0%
- Other Revenue$500K-28.6%0.3%
Forward guidance
LivaNova expects worldwide net sales for full-year 2020 to decline between 7 and 17 percent on a constant-currency basis. Adjusted diluted earnings per share from continuing operations for 2020 are expected to be in the range of $1.15 to $1.35, which reflects an incremental impact of $0.28 due to financing activities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+1.2%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+1.3%
Avg return
30 days after
58%
26 / 45 earnings
Positive
+23.3%
Q1 2025
Best reaction
-19.9%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +15.1% | +21.7% | +25.5% | |
| Q4 2025 | +0.8% | +1.8% | -10.4% | |
| Q3 2025 | -5.8% | -5.7% | +17.5% | |
| Q1 2025 | +23.3% | +28.6% | +30.7% | |
| Q4 2024 | -15.8% | -15.9% | -20.0% | |
| Q3 2024 | -2.5% | -7.5% | -0.9% | |
| Q2 2024 | -5.8% | -11.8% | -1.8% | |
| Q1 2024 | +12.9% | +12.3% | +9.5% | |
| Q4 2023 | +6.9% | +6.4% | +6.4% | |
| Q3 2023 | -0.8% | -0.9% | -6.4% | |
| Q2 2023 | +7.0% | +9.1% | +4.0% | |
| Q1 2023 | +0.6% | -0.0% | -0.6% | |
| Q4 2022 | -9.6% | -12.1% | -23.6% | |
| Q3 2022 | +2.2% | +6.6% | +19.1% | |
| Q2 2022 | -3.0% | -2.2% | -13.9% | |
| Q1 2022 | -13.2% | -21.8% | -9.1% | |
| Q4 2021 | +7.9% | +9.4% | +8.6% | |
| Q3 2021 | +15.3% | +15.9% | +2.4% | |
| Q2 2021 | +8.0% | +7.1% | +1.1% | |
| Q1 2021 | +3.8% | +1.4% | +0.8% | |
| Q4 2020 | +3.5% | +3.6% | +2.6% | |
| Q3 2020 | +1.0% | -4.5% | +8.9% | |
| Q2 2020 | -11.0% | -17.2% | -14.9% | |
| Q1 2020 | -5.8% | -10.4% | -5.1% | |
| Q4 2019 | +3.3% | +5.2% | -34.6% | |
| Q3 2019 | -6.8% | -6.4% | +10.4% | |
| Q2 2019 | +5.8% | +1.7% | +2.5% | |
| Q1 2019 | +5.2% | +8.8% | +4.4% | |
| Q4 2018 | -4.2% | -3.1% | +0.0% | |
| Q3 2018 | +5.6% | +6.9% | -6.6% | |
| Q2 2018 | +12.2% | +10.3% | +14.0% | |
| Q1 2018 | -8.0% | -6.7% | +5.9% | |
| Q4 2017 | +2.4% | +0.8% | +1.1% | |
| Q3 2017 | +11.7% | +9.1% | +20.3% | |
| Q2 2017 | +1.4% | +1.5% | +7.7% | |
| Q1 2017 | +4.0% | +4.8% | +7.0% | |
| Q4 2016 | +4.2% | -2.0% | -2.8% | |
| Q3 2016 | -19.9% | -21.0% | -19.3% | |
| Q2 2016 | +14.9% | +11.1% | +12.0% | |
| Q1 2016 | -3.5% | — | — | |
| Q4 2014 | -0.0% | — | — | |
| Q4 2013 | -0.0% | — | — | |
| Q4 2015 | -1.1% | — | — | |
| Q2 2015 | +1.9% | — | — | |
| Q3 2015 | -10.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro